These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
202 related articles for article (PubMed ID: 29726056)
1. Evaluation of compliance with isotretinoin PPP recommendations and exploration of reasons for non-compliance: Survey among French-speaking health care professionals and patients in Belgium. Lelubre M; Hamdani J; Senterre C; Amighi K; Peres M; Schneider MP; Bugnon O; De Vriese C Pharmacoepidemiol Drug Saf; 2018 Jun; 27(6):668-673. PubMed ID: 29726056 [TBL] [Abstract][Full Text] [Related]
2. Compliance with pregnancy prevention programmes of isotretinoin in Europe: a systematic review. Crijns HJ; Straus SM; Gispen-de Wied C; de Jong-van den Berg LT Br J Dermatol; 2011 Feb; 164(2):238-44. PubMed ID: 20716214 [TBL] [Abstract][Full Text] [Related]
3. Healthcare professional surveys to investigate the implementation of the isotretinoin Pregnancy Prevention Programme: a descriptive study. Crijns I; Mantel-Teeuwisse A; Bloemberg R; Pinas E; Straus S; de Jong-van den Berg L Expert Opin Drug Saf; 2013 Jan; 12(1):29-38. PubMed ID: 23163396 [TBL] [Abstract][Full Text] [Related]
4. Dermatologists' level of compliance with the prescription guidelines of isotretinoin for females of childbearing potential. AlGhamdi KM; Khurram H; Asiri YA; Mandil A Int J Dermatol; 2011 Sep; 50(9):1094-8. PubMed ID: 22126870 [TBL] [Abstract][Full Text] [Related]
5. Isotretinoin use and compliance with the Dutch Pregnancy Prevention Programme: a retrospective cohort study in females of reproductive age using pharmacy dispensing data. Teichert M; Visser LE; Dufour M; Rodenburg E; Straus SM; De Smet PA; Stricker BH Drug Saf; 2010 Apr; 33(4):315-26. PubMed ID: 20297863 [TBL] [Abstract][Full Text] [Related]
6. Implementation of the harmonized EU isotretinoin Pregnancy Prevention Programme: a questionnaire survey among European regulatory agencies. Crijns I; Straus S; Luteijn M; Gispen-de Wied C; Raine J; de Jong-van den Berg L Drug Saf; 2012 Jan; 35(1):27-32. PubMed ID: 22050373 [TBL] [Abstract][Full Text] [Related]
9. Assessing the availability of the teratogenic drug isotretinoin outside the pregnancy prevention programme: a survey of e-pharmacies. Lagan BM; Dolk H; White B; Uges DR; Sinclair M Pharmacoepidemiol Drug Saf; 2014 Apr; 23(4):411-8. PubMed ID: 24493556 [TBL] [Abstract][Full Text] [Related]
10. Optimizing Isotretinoin Treatment of Acne: Update on Current Recommendations for Monitoring, Dosing, Safety, Adverse Effects, Compliance, and Outcomes. Landis MN Am J Clin Dermatol; 2020 Jun; 21(3):411-419. PubMed ID: 32107726 [TBL] [Abstract][Full Text] [Related]
11. Pregnancy prevention among women taking isotretinoin: failure to comply with the recommendations. Boucher N; Beaulac-Baillargeon L Can Fam Physician; 2006 Mar; 52(3):338-9. PubMed ID: 16926960 [TBL] [Abstract][Full Text] [Related]
12. Compliance with pregnancy prevention plan recommendations in 8672 French women of childbearing potential exposed to acitretin. Raguideau F; Mezzarobba M; Zureik M; Weill A; Ricordeau P; Alla F Pharmacoepidemiol Drug Saf; 2015 May; 24(5):526-33. PubMed ID: 25753265 [TBL] [Abstract][Full Text] [Related]
13. A pregnancy-prevention program in women of childbearing age receiving isotretinoin. Mitchell AA; Van Bennekom CM; Louik C N Engl J Med; 1995 Jul; 333(2):101-6. PubMed ID: 7777014 [TBL] [Abstract][Full Text] [Related]
14. Isotretinoin exposure during pregnancy: assessment of spontaneous reports in France. Autret-Leca E; Kreft-Jais C; Elefant E; Cissoko H; Darrouzain F; Grimaldi-Bensouda L; Attia S; Jonville-Béra AP Drug Saf; 2010 Aug; 33(8):659-65. PubMed ID: 20635824 [TBL] [Abstract][Full Text] [Related]
15. [Isotretinoin (Roaccutane) in women of childbearing age: failure of following prescription guidelines]. Autret E; Radal M; Jonville-Béra AP; Goehrs JM Ann Dermatol Venereol; 1997; 124(8):518-22. PubMed ID: 9740842 [TBL] [Abstract][Full Text] [Related]
16. A comparative review of the isotretinoin pregnancy risk management programs across four continents. Kovitwanichkanont T; Driscoll T Int J Dermatol; 2018 Sep; 57(9):1035-1046. PubMed ID: 29508918 [TBL] [Abstract][Full Text] [Related]
17. The effect of drug consultation center guidance on contraceptive use among women using isotretinoin: a randomized, controlled study. Tsur L; Kozer E; Berkovitch M J Womens Health (Larchmt); 2008 May; 17(4):579-84. PubMed ID: 18447762 [TBL] [Abstract][Full Text] [Related]
18. Trends in adherence to a revised risk management program designed to decrease or eliminate isotretinoin-exposed pregnancies: evaluation of the accutane SMART program. Brinker A; Kornegay C; Nourjah P Arch Dermatol; 2005 May; 141(5):563-9. PubMed ID: 15897377 [TBL] [Abstract][Full Text] [Related]
19. Fetal exposure to isotretinoin-an international problem. Garcia-Bournissen F; Tsur L; Goldstein LH; Staroselsky A; Avner M; Asrar F; Berkovitch M; Straface G; Koren G; De Santis M Reprod Toxicol; 2008 Jan; 25(1):124-8. PubMed ID: 18077132 [TBL] [Abstract][Full Text] [Related]
20. Compliance with pregnancy prevention measures during isotretinoin therapy. Collins MK; Moreau JF; Opel D; Swan J; Prevost N; Hastings M; Bimla Schwarz E; Korb Ferris L J Am Acad Dermatol; 2014 Jan; 70(1):55-9. PubMed ID: 24157382 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]